TY - JOUR
T1 - Tumor suppressors govern insulin-like growth factor signaling pathways
T2 - Implications in metabolism and cancer
AU - Werner, H.
N1 - Funding Information:
Work in the laboratory of HW is supported by grants from the Israel Science Foundation, Israel Cancer Association, Insulin-Dependent Diabetes Trust (IDDT, UK), Israel Cancer Research Fund (ICRF, New York and Montreal) and US-Israel Binational Science Foundation.
PY - 2012/5/31
Y1 - 2012/5/31
N2 - The insulin-like growth factor (IGF) axis mediates growth, differentiation and developmental processes, and is also involved in control of metabolic activities. Deregulation of IGF axis expression and action is linked to a number of pathologies, ranging from metabolic disorders to growth deficits and cancer development. Activation of the IGF signaling pathway is a crucial prerequisite for malignant transformation. In addition, overexpression of the IGF-1 receptor (IGF-1R) constitutes a typical hallmark of most types of cancer. A series of tumor suppressors have been identified whose mechanisms of action involve transcriptional suppression of the IGF-1R gene. These tumor suppressors include the p53/p63/p73 family, breast cancer gene-1, von-Hippel Lindau protein, Wilms tumor-1 and others. Comprehensive analyses have identified a complex bidirectional interplay between the IGF and tumor-suppressor signaling pathways. These interactions are of major importance in terms of cancer development and may also predict responsiveness to IGF-1R-targeted therapies. Furthermore, the insulin/IGF system has a pivotal role in the regulation of cancer cell metabolism. Deregulation of IGF axis components by mutated tumor-suppressor proteins may lead to metabolic perturbations, with ensuing pathological consequences.
AB - The insulin-like growth factor (IGF) axis mediates growth, differentiation and developmental processes, and is also involved in control of metabolic activities. Deregulation of IGF axis expression and action is linked to a number of pathologies, ranging from metabolic disorders to growth deficits and cancer development. Activation of the IGF signaling pathway is a crucial prerequisite for malignant transformation. In addition, overexpression of the IGF-1 receptor (IGF-1R) constitutes a typical hallmark of most types of cancer. A series of tumor suppressors have been identified whose mechanisms of action involve transcriptional suppression of the IGF-1R gene. These tumor suppressors include the p53/p63/p73 family, breast cancer gene-1, von-Hippel Lindau protein, Wilms tumor-1 and others. Comprehensive analyses have identified a complex bidirectional interplay between the IGF and tumor-suppressor signaling pathways. These interactions are of major importance in terms of cancer development and may also predict responsiveness to IGF-1R-targeted therapies. Furthermore, the insulin/IGF system has a pivotal role in the regulation of cancer cell metabolism. Deregulation of IGF axis components by mutated tumor-suppressor proteins may lead to metabolic perturbations, with ensuing pathological consequences.
KW - BRCA1
KW - IGF
KW - IGF-1 receptor
KW - Insulin-like growth factors
KW - P53
KW - Tumor suppressors
UR - http://www.scopus.com/inward/record.url?scp=84861682298&partnerID=8YFLogxK
U2 - 10.1038/onc.2011.447
DO - 10.1038/onc.2011.447
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 21963847
AN - SCOPUS:84861682298
SN - 0950-9232
VL - 31
SP - 2703
EP - 2714
JO - Oncogene
JF - Oncogene
IS - 22
ER -